GSK sees 'modest' impact on trials, getting head down for 'busy few months' on COVID-19 work

GlaxoSmithKline is following suit with fellow British Big Pharma AstraZeneca in downplaying the overall risk to its trials during the pandemic.

AZ said in its financials this week that it wasn’t expecting much of a hit on its late-stage trials, many of which are focused around its checkpoint inhibitor cancer drug Imfinzi.

Now, GSK is saying it’s also confident it won’t be too hard done by in terms of trial delays, with Chief Scientific Officer Hal Barron saying in its first-quarter results this is due to “the ability for us to come up with somewhat novel ways of doing these trials, we're confident that the impact is modest.”